Pharmaceutical - Pharmaceutical


Current filters:


Popular Filters

6801 to 6825 of 7049 results

Letter to the Editor: Canadian intellectual property


Dear, The Pharma Letter: The characterization of the CMAJ article by Paul Grootendorst and Aidan Hollis…

GenericsNorth AmericaPatentsPharmaceutical

Kohl-Grassley generic drug bill would save US taxpayers nearly $4.8 billion, says CBO


A new estimate from the USA’s Congressional Budget Office (CBO) estimate finds that a bipartisan…

GenericsNorth AmericaPatentsPharmaceuticalPoliticsPricing

Salix Pharma to buy Oceana for $300 million; posts 3rd-qtr profit


With the aim of improving its innovate products franchise, US drugmaker Salix Pharmaceuticals (Nasdaq:…

FinancialMergers & AcquisitionsOceana TherapeuticsPharmaceuticalSalix Pharmaceuticals

Merck Serono expands osteoarthritis collaboration with Ablynx


Merck Serono, a division of Germany’s Merck KGaA (MRK: DE) has entered into a third agreement with…

AblynxAnti-Arthritics/RheumaticsLicensingMerck SeronoPharmaceuticalResearch

Timothy Wright named global head, development, at Novartis Pharma


Swiss drug major Novartis (NOVN: VX) announced the appointment of Timothy Wright, as global head, development,…


Amylin diabetes drug exenatide deal with Eli Lilly terminated, with $1.45 billion settlement to Lilly


Shares of US biotech firm Amylin Pharmaceuticals fell 8.4% to $10.01 in pre-market trading yesterday,…

AmylinBiotechnologyBydureonByettaDiabetesEli LillyExenatide InjectionLicensingPharmaceutical

Disappointment for AstraZeneca and Targacept as antidepressant fails to meet Ph III endpoint


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Targacept (Nasdaq: TRGT) yesterday reported disappointing…


Transgene to seek partner for HCV vaccine TG4040 on strong Ph II results


French biotech firm Transgene (Euronext Paris: FR0005175080) has revealed interim data showing a substantial…


Strong 3rd-quarter 2011 sales growth at Lundbeck, but write-off hits profit


Danish CNS drug specialist Lundbeck (LUND: DC) has reported a strong set of financial results for the…


Tranzyme Pharma extends drug discovery collaboration with Bristol-Myers Squibb


USA-based Tranzyme Pharma (Nasdaq: TZYM) says it has extended its chemistry-based drug discovery collaboration…

Bristol-Myers SquibbLicensingPharmaceuticalResearchTranzyme

Will the USA’s Hatch-Waxman lock be sprung in 2012? asks HP&M lawyer


In the USA, there have been rumors for several weeks that, once the ball gets rolling in Congress with…

GenericsLegalNorth AmericaPharmaceuticalPoliticsRegulation

Recordati’s Normosang now approved in Russia; posts strong financials


Italian drugmaker Recordati (REC: MI) and wholly-owned subsidiary Orphan Europe announced that Normosang,…

EuropeFinancialNormosangPharmaceuticalRare diseasesRecordatiRegulation

Another call for reform of Canada’s pharma intellectual property laws


Canada's pharmaceutical intellectual property laws need major reform to encourage and protect innovation…

North AmericaPatentsPharmaceutical

Emerging therapies will drive prostate cancer drug market to $10.1 billion in 2020


Driven by the launches of several promising emerging therapies, the prostate cancer drug market will…

Astellas PharmaBiotechnologyGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalZytiga

South Korean govt to slash drug prices 14%


South Korea’s Ministry of Health and Welfare has issued an advance notice of the legislation of…


FDA accepts VIVUS NDA filing for Qnexa with PDUFA set for April 2012


There was good news for US drugmaker VIVUS (Nasdaq: VVUS) in its long-running battle to get its weight-loss…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

Added indication for Bristol-Myers’ Erbitux approved by FDA


The US Food and Drug Administration yesterday approved US drug major Bristol-Meyers Squibb’s (NYSE:…

Bristol-Myers SquibbErbituxNorth AmericaOncologyPharmaceuticalRegulation

Vertex’ Incivek set to break record for fastest product launch


Vertex Pharmaceuticals’ (Nasdaq: VRTX) new hepatitis C drug Incivek (telaprevir) is being touted…

FinancialIncivekMarkets & MarketingPharmaceuticalVertex

AstraZeneca launches new Crestor savings card in USA, as generic Lipitor about to debut


The US subsidiary of Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday launched a new savings…

AstraZenecaCardio-vascularCrestorGenericsLipitorNorth AmericaPfizerPharmaceuticalPricing

Novo Nordisk says DegludecPlus provides superior glycemic control vs Lantus


Denmark-based insulin giant Novo Nordisk (NVO: N) yesterday announced positive clinical results from…

DegludecDegludecPlusDiabetesLantusNovo NordiskPharmaceuticalResearchSanofi

Small-molecule cancer drug revenues set to reach $27.3 billion in 2015, predicts Visiongain


Rising disease prevalence, along with advances in pharmacotherapy and diagnostics, will stimulate the…

Markets & MarketingOncologyPharmaceutical

Study identifies factors linked with better medication response for treatment of juvenile arthritis


Among patients with juvenile idiopathic arthritis (JIA) who initiated treatment with the drug etanercept…


US FDA clears Bayer/Johnson & Johnson’s Xarelto for stroke risk reduction in AF patients


In what was much-awaited good news for German drug major Bayer (BAY: DE), its US subsidiary announced…

BayerCardio-vascularJanssen PharmaceuticaJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Pfizer returns rights to TNF-alpha targeting nanobodies to Ablynx


Shares of Belgian drug developer Ablynx [Euronext Brussels: ABLX] fell 18.2% to 2.93 euros in morning…


6801 to 6825 of 7049 results

Back to top